ARCT Stock Overview
A late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ARCT from our risk checks.
Arcturus Therapeutics Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.38 |
| 52 Week High | US$43.81 |
| 52 Week Low | US$17.52 |
| Beta | 2.65 |
| 1 Month Change | 19.66% |
| 3 Month Change | -13.52% |
| 1 Year Change | 14.70% |
| 3 Year Change | 13.42% |
| 5 Year Change | 370.64% |
| Change since IPO | 223.48% |
Recent News & Updates
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09
Recent updates
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat
May 11Arcturus: Biotech With Great Potential In Covid-19 Vaccine Space
Apr 25Shareholder Returns
| ARCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.6% | 0.7% | 1.2% |
| 1Y | 14.7% | 5.0% | 27.7% |
Return vs Industry: ARCT exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: ARCT underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ARCT volatility | |
|---|---|
| ARCT Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ARCT's share price has been volatile over the past 3 months.
Volatility Over Time: ARCT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 180 | Joe Payne | arcturusrx.com |
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis.
Arcturus Therapeutics Holdings Inc. Fundamentals Summary
| ARCT fundamental statistics | |
|---|---|
| Market cap | US$803.92m |
| Earnings (TTM) | -US$107.30m |
| Revenue (TTM) | US$124.53m |
7.0x
P/S Ratio-8.1x
P/E RatioIs ARCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARCT income statement (TTM) | |
|---|---|
| Revenue | US$124.53m |
| Cost of Revenue | US$15.96m |
| Gross Profit | US$108.57m |
| Other Expenses | US$215.87m |
| Earnings | -US$107.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 87.19% |
| Net Profit Margin | -86.16% |
| Debt/Equity Ratio | 0% |
How did ARCT perform over the long term?
See historical performance and comparison